Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.lilly.com
Eli Lilly and Company News Releases
Get the latest updates from Eli Lilly and Company News Releases directly as they happen.
Follow now 272 followers
Latest posts
Last updated 6 days ago
Lilly to acquire Orna Therapeutics to advance cell therapies
6 days ago
Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the...
Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance
11 days ago
Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume...
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
15 days ago
The $3.5 billion Lehigh Valley site will develop Lilly's next-generation weight-loss medicines...
Lilly Responds to American Hospital Association Letter to HRSA About 340B Program Changes
16 days ago
To prevent fraud, waste, and abuse in the 340B program, Lilly has...
Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
25 days ago
INDIANAPOLIS , Jan. 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer
26 days ago
INDIANAPOLIS , Jan. 20, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE...
NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery In the Age of AI
about 1 month ago
News Summary: NVIDIA and Lilly bring together a world-leading, multidisciplinary team of...
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight
about 1 month ago
At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50%...
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
about 1 month ago
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies...
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
about 2 months ago
In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for...
Lilly to participate in J.P. Morgan Healthcare Conference
2 months ago
INDIANAPOLIS , Dec. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
2 months ago
As monotherapy, imlunestrant demonstrated an 11.4-month numeric improvement in median OS versus...